ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,967.23
-0.88%
US Tech 100
16,587.60
-2.06%
Dow Jones
37,986.40
0.56%
Brent Oil
86.595
0.21%
Bitcoin
64,179.68
1.06%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Rocket Pharmaceuticals Inc (RCKT) Quote

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc (RCKT)

NASDAQ
22.95
-0.53
( -2.26% )
Updated: 15:56:02
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
22.95
Bid
22.92
Ask
22.95
Volume
677,070
22.32 Day's Range 23.64
14.89 52 Week Range 32.525
Market Cap
8.145M
Previous Close
23.48
Open
23.29
Last Trade
100
@
22.8883
(average)
Last Trade Time
15:56:08
Financial Volume
$ 15,742,181
VWAP
23.2504
Average Volume (3m)
717,078
Shares Outstanding
90,504,248
Dividend Yield
-
PE Ratio
-0.03
Earnings Per Share (EPS)
-2.71
Revenue
-
Net Profit
-245.6M

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesio... Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rocketpharma.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Rocket Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RCKT. The last closing price for Rocket Pharmaceuticals was $23.48. Over the last year, Rocket Pharmaceuticals shares have traded in a share price range of $ 14.89 to $ 32.525.

Rocket Pharmaceuticals currently has 90,504,248 shares outstanding. The market capitalization of Rocket Pharmaceuticals is $8.15 million. Rocket Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.03.

Rocket Pharmaceuticals (RCKT) Options Flow Summary

RCKT Options Flow

Overall Flow

Bullish

Net Premium

56k

Calls / Puts

200.00%

Buys / Sells

50.00%

OTM / ITM

50.00%

Sweeps Ratio

0.00%

RCKT Latest News

More News

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Positive, previously disclosed results from the global Phase 1/2 trial demonstrated genetic and phenotypic correction combined with hematologic stabilization extending out to 42 months after...

April 02 2024
Business Wire

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key...

March 26 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

March 04 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 04 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

February 29 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

February 29 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 26 2024
Edgar (US Regulatory)

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

  Advancing leading pipeline of six disclosed programs across AAV cardiovascular and LV hematology portfolios; all milestones remain on track for 2024 Expanding commercial capabilities to support...

February 26 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.2-8.7475149105425.1525.551322.3266821823.95954545CS
4-5-17.889087656527.9527.9822.3259933425.19434836CS
12-5.77-20.090529247928.7231.4722.3271707827.63634964CS
266.1536.607142857116.832.52516.5580381225.81191547CS
524.1522.074468085118.832.52514.8986829622.83075976CS
156-20.3-46.93641618543.2549.667.56573956021.35004259CS
2605.6832.8894035917.2767.487.56559406223.39872839CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
$ 0.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 0.00
(0.00%)
0
AACGATA Creativity Global
$ 0.00
(0.00%)
0

RCKT Discussion

View Posts
Monksdream Monksdream 4 months ago
RCKT new 52 week high
👍️0
make it happen make it happen 7 months ago
How's it up 38% @ $21.00 PPS when diluting $175,000,000 million @ $16.00??
👍️0
trkyhntr trkyhntr 3 years ago
I have been away at hunting camp for a few weeks, and when I got back I was pleasantly surprised. This puppy has doubled! Any thoughts as to how much more upside there is?
👍️0
ClayTrader ClayTrader 3 years ago
* * $RCKT Video Chart 12-09-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Glider549 Glider549 4 years ago
Check out Seeking Alpha, January 27, article.
Lots of insider buying and Fast Track status.
👍️0
RUSTYJ RUSTYJ 5 years ago
How you figure a lot power , Gravity takes it down
👍️0
investor86 investor86 6 years ago
This got a lot of power!!
👍️0
trkyhntr trkyhntr 6 years ago
This is a new board for this stock. Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
👍️0

Your Recent History

NASDAQ
RCKT
Rocket Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved